Development of Therapeutic Agents Handbook

PREFACE ix
<p>CONTRIBUTORS xi</p>
<p>PART I FUNDAMENTAL CONCEPTS 1</p>
<p>1. Current Needs for New Therapeutic Agents and Discovery Strategies A Systems Pharmacology Approach 3<br /> Sophie C. Desbiens and David H. Farb</p>
<p>2. Target Selection in Drug Discovery 25<br /> Charles F. Albright</p>
<p>3. New Drug Applications 35<br /> John S. McInnes and Donald O. Beers</p>
<p>4. From Concept to the Clinics: Development of Cancer Therapeutics 47<br /> Balveen Kaur, Gregory B. Lesinski, and Abhik Ray Chaudhary</p>
<p>5. Development of Countermeasures for Bioterrorism in the United States 73<br /> Gregory H. Levine and Jeffrey I. Handwerker</p>
<p>6. Development and Application of Conformation–Selective Integrin Antibodies 91<br /> Nathan S. Astrof, Dan Peer, and Motomu Shimaoka</p>
<p>7. Pain Management Market Overview 113<br /> Anita Holdcroft</p>
<p>8. Antiviral Market Overview 127<br /> Anita Arora, Natalia Mendoza, and Stephen K. Tyring</p>
<p>PART II METHODS AND TECHNIQUES IN DRUG DISCOVERY AND DEVELOPMENT 145</p>
<p>9. High–Throughput Screening for Small–Molecule Drug Discovery 147<br /> C. Parker and J.–H. Zhang</p>
<p>10. Mass Spectrometry 181<br /> Robert D. English and Anthony M. Haag</p>
<p>11. Molecular Screening for Therapeutic Agents 207<br /> R. Damoiseaux</p>
<p>12. Accelerator Mass Spectrometry and Positron Emission Tomography in Human Microdosing 241<br /> Zhengdong Cheng</p>
<p>13. Development of Antimicrobial Peptides as Therapeutic Agents 285<br /> Robert S. Hodges, Ziqing Jiang, James Whitehurst, and Colin T. Mant</p>
<p>14. Antibodies for Human Diseases 359<br /> Guo–Liang Yu and Jian Ni</p>
<p>15. Combinatorial Compounds and Drug Discovery 399<br /> James C. Bigelow</p>
<p>16. Locoregional Chemoradiotherapy of Cancer Using Hydrogel 413<br /> David J. Yang, Ali Azhdarinia, Hiroaki Kurihara, and E. Edmund Kim</p>
<p>17. RNAi–Mediated Therapeutics 425<br /> Nuria Morral and Scott R. Witting</p>
<p>18. Crystallography 445<br /> Carl H. Schwalbe</p>
<p>19. PEGylation 463<br /> Sanju Dhawan, Deepak N. Kapoor, Rishi Kapil, Mano Kumarj, and Ankur Bansal</p>
<p>20. Gold Standard Animal Models 517<br /> Carol Casteneda and Michael S. LaPointe</p>
<p>21. Discovery of Vaccine Adjuvants 533<br /> Fiona A. Sharp and Ed C. Lavelle</p>
<p>22. Oral Delivery of Macromolecules for the Development of Therapeutic Agents 547<br /> Hye J. Lee and Chanmi Choi</p>
<p>23. Aerosol Drug Delivery to the Lungs 565<br /> Andrew R. Martin and Warren H. Finlay</p>
<p>24. Resistance to Antiplatelet Theraphy 589<br /> Paul A. Gurbel, Udaya S. Tantry, and Mark J. Antonino</p>
<p>25. Antibiotic Development 611<br /> Robert L. Bettiker and Jason C. Gallagher</p>
<p>PART III THERAPEUTIC TOPICS 629</p>
<p>26. Antimicrobial Resistance in Biofi lms: A Sticky Situation 631<br /> Shu Yeong Queck and Michael Otto</p>
<p>27. Drotrecogin Alfa Activated (Recombinant Human Activated Protein C, Xigris) 645<br /> Byungse Suh and Rafi k Samuel</p>
<p>28. Anti–Inflammatory Therapeutics 655<br /> Marion M. Chan and Dunne Fong</p>
<p>29. Anti–Inflammatory/Analgesics: An In–depth Look at p38 MAP Kinases 673<br /> Kelly L. Brown</p>
<p>30. Cardiovascular Disease: In–Depth Look 707<br /> Nicholas B. Norgard and Mazen Abu–Fadel</p>
<p>31. Ezetimibe and Cholesterol Absorption 723<br /> Stefan Oswald and Werner Siegmund</p>
<p>32. Cardiology In–Depth Look: Kinases as Therapeutic Targets in the Heart 743<br /> Karin Mauer and J. Emilio Exaire</p>
<p>33. Statins in the Reduction of Cardiovascular Events 773<br /> Rajesh Sachdeva, Bradley Hughes, and Jawahar L. Mehta</p>
<p>34. Cardiology In–Depth Look: Advances in Antiplatelet Theraphy 785<br /> Karin Mauer and Jorge F. Saucedo</p>
<p>35. Gastrointestinal Disorders: A Focus on Acid–Suppressive Agents 813<br /> Brian Hemstreet</p>
<p>36. Pharmacology of Vasopressin and the Renin Angiotension Aldosterone System 825<br /> Elizabeth J. Brant and Julian L. Seifter</p>
<p>37. New Drugs and Nutaceutical in the Treatment of Osteoarthristis 847<br /> Y. Henrotin and J. Y. Reginster</p>
<p>38. Development of Anticytokine Agents for Rheumatoid Arthritis 881<br /> Jonathan Sherlock, Christopher D. Buckley, and Karim Raza</p>
<p>39. Overview of CNS Neuropharmaceuticals 897<br /> Tauser Roxana–Georgiana and Antohe Dan–Stefan</p>
<p>40. Thinking Outside the Box in Alzheimer Disease Treatment 929<br /> Rudy J. Castellani, Michael W. Marlatt, Akihiko Nunomura, Paula I. Moreira, Hyoung–Gon Lee, Gemma Casadesus, Xiogwei Zhu, George Perry, and Mark A, Smith</p>
<p>41. Neurotrophic Factors as Novel Therapeutic Targets 943<br /> Stephen D. Skaper</p>
<p>42. Oncology 963<br /> Arkadiusz Z. Dudek and Steven F. Powell</p>
<p>43. Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia 999<br /> Muhammad Mansoor Alam and Moshe Talpaz</p>
<p>44. Aromatase Inhibitors for Breast Cancer 1011<br /> Akm Hossain and Jame Abraham</p>
<p>45. Evolution of Selective Estrogen and Androgen Receptor Modulators: Status of Current Therapy and New Drug Development 1019<br /> Gregory T. Wurz and Michael W. DeGregorio</p>
<p>46. In–Depth Look: anti–TNF– Therapies 1045<br /> Satadal Chatterjee and Shobhan Gaddameedhi</p>
<p>47. Development of Therapeutic Agents: The Maternal Fetal Perspective 1093<br /> C. Gedeon, F. Garcia Bournissen and G. Koren</p>
<p>48. History of Antipsychotic Drug Development 1111<br /> Shankar S. Gollapudi and Rajan Radhakrishnan</p>
<p>49. Radiopharmaceuticals and Medical Imaging: Development of Radioimmumoconjugates for Radioimmunoimaging and Radioimmunotherapy of Malignant Diseases 1137<br /> Gang Niu and Xiaoyuan Chen</p>
<p>50. Therapeutic Drug Development for Kidney Diseases 1159<br /> Mitchell H. Rosner, Joshua King, and Peter Monteleone</p>
<p>51. Targeting Chemokines and Angiogenesis in Arthritis 1185<br /> Zoltan Szekaneez and Alisa E Koch</p>
<p>52. Development of Therapeutic Agents: Methods and Approaches in the Development of Vaccines against Protozoan Parasites 1207<br /> Catherine Ivory and Kris Chadee</p>
<p>53. Toxicology 1221<br /> John H. Duffus</p>
<p>54. The Development of Phosphodiesterase 4 Inhibitors for Allergic and Nonallergic Infl ammatory Diseases of the Airways 1233<br /> Mark A. Giembycz</p>
<p>INDEX 1251</p>